Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/joph/volume-2015/324841/figures/324841.fig.004a.svgz" name="324841.fig.004a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Median VA change in Snellen (20/value)</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/joph/volume-2015/324841/figures/324841.fig.004b.svgz" name="324841.fig.004b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Median VA change in decimal score</td></tr></table>

<div>Median VA change in the treated eye from baseline in (a) Snellen (20/value) and (b) decimal score in the subgroup with at least 6 months of follow-up in unilateral and bilateral patients with DME. BSL, baseline; DME, diabetic macular edema; VA, visual acuity.</div>

Journal of Ophthalmology

fig4

Figure 4

Figure 4: Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study) 